title: [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
abstract: Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed.
authors.affiliation: Hôtel-Dieu de Paris, université Paris Descartes, 1, place du Parvis-Notre-Dame, 75004 Paris, France. Electronic address: soubraneg@gmail.com.
authors.forename: G
authors.initials: G
authors.lastname: Soubrane
authors.affiliation: Hôpital ophtalmique Jules-Gonin, avenue de France 15, 1000 Lausanne, Suisse.
authors.forename: F
authors.initials: F
authors.lastname: Behar-Cohen
mesh_terms: D002908:Chronic Disease; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy*; D004343:Drug Implants; D005446:Fluocinolone Acetonide / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology
chemical_list: D004343:Drug Implants; D005446:Fluocinolone Acetonide
keywords: Acétonide de fluocinolone; Diabetic macular edema; Essai clinique randomisé; FAME; Fluocinolone acetonide; Foveal thickness; ILUVIEN(®); Long-term results; Micro-implant; Randomized clinical trial; Review; Revue; Résultats à long terme; Épaisseur fovéale; Œdème maculaire diabétique